Helix BioPharma Corp.
HBP
Rank in Stocks
#23049
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian... Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Share Price
$0.59484187
Last synced: 2026-11-10
Market Cap
$45.43M
Change (1 day)
-6.67%
Change (1 year)
-64.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Helix BioPharma Corp. (HBP)
Category
Healthcare
Operating Margin for Helix BioPharma Corp. (HBP)
Operating Margin as of November 2026 TTM: 0.00%
According to Helix BioPharma Corp.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Helix BioPharma Corp. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -248.80% | -9.63% |
| 2011 | -275.31% | -8.52% |
| 2010 | -300.95% | -17.78% |
| 2009 | -366.02% | 62.07% |
| 2008 | -225.84% | 14.54% |
| 2007 | -197.17% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | - |
US
|
|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Helix BioPharma Corp.'s operating margin
What was Helix BioPharma Corp.'s operating margin in 2025?
In 2025, Helix BioPharma Corp.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Helix BioPharma Corp.'s operating margin changed since 2020?
From 2020 to 2025, Helix BioPharma Corp.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Helix BioPharma Corp.'s operating margin compare with similar companies?
Helix BioPharma Corp.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.